4D Molecular Therapeutics, Inc. - 8-K Filing
On June 24, 2026, 4D Molecular Therapeutics entered into a $200 million loan agreement with Hercules Capital. The senior secured term loans include an immediate $20 million draw and up to $180 million in future tranches subject to milestones or lender discretion. Loans mature on June 1, 2031, bear interest rates starting at 8.75% for the initial tranche and 9.25% for others, with financial covenants tied to cash reserves and market capitalization. (Items: 1.01 Entry into a Material Definitive Agreement, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information set forth u)
Tickers: $FDMT